Biopharma · FDA Approvals · Stock
NTRB Nutriband
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two rep…
Assets on file: AVERSA FENTANYL
Catalyst calendar
Dated catalysts for NTRB, including recently decided ones.
Nothing scheduled in this window.
Recent first-hand events
Every first-hand event for NTRB, newest first.
NTRBNutribandNutriband completes FDA CMC meeting for AVERSA FENTANYL
Nutriband received final FDA meeting minutes confirming the 505(b)(2) NDA pathway and providing guidance on CMC plans, registration batch strategy, and Category 1 in vitro abuse-deterrent studies. The company is incorporating this feedback as it advances toward an IND filing to support a Human Abuse Potential clinical study.
Peers by market cap
Companies in the same sector closest to NTRB in market value.
LUCDLucid DiagnosticsMarket cap $77.3M · 1 tracked drug
ATRAAtara BiotherapeuticsMarket cap $80.4M · 1 tracked drug · 3 upcoming catalysts
CINGCingulateMarket cap $72.4M · 1 tracked drug · 1 upcoming catalyst
GRMLGreenland MinesMarket cap $70.3M
CPIXCumberland PharmaceuticalsMarket cap $70.3M · 1 tracked drug · 1 upcoming catalyst
PMVPPMV PharmaceuticalsMarket cap $70.0M · 1 tracked drug · 2 upcoming catalysts
TELOTelomir PharmaceuticalsMarket cap $68.8M · 1 tracked drug · 1 upcoming catalyst
TENXTenax TherapeuticsMarket cap $67.0M · 1 tracked drug · 2 upcoming catalysts